Orexigen Therapeutics, Inc. v. Actavis Labs. FL, Inc.
282 F. Supp. 3d 793
D. Del.2017Background
- Orexigen sued Actavis (ANDA filer) alleging infringement of three patents directed to naltrexone/bupropion combination therapies for weight loss (U.S. Pat. Nos. 7,462,626; 7,375,111; 8,916,195). Bench trial held June 5–7, 2017.
- Patents-in-suit: the '626 and '195 are method claims (treatment/administering; specific dissolution profile in '195 claim 11); the '111 claims a single oral dosage fixed combination of sustained‑release bupropion and naltrexone.
- Actavis defended on noninfringement and invalidity grounds (written description as to the '195; obviousness as to the '111 and '626). Actavis also moved to admit a 2003 fax from Dr. Gadde describing earlier patient treatments.
- Court admitted the Gadde fax narrowly (as evidence Dr. Gadde shared the 2003 communication with Orexigen), but rejected treating it as prior art or as substantive proof of 1997/2000 treatments.
- Court found (1) claim 11 of the '195 patent satisfies written description; (2) claims 26 and 31 of the '626 patent and claim 1 of the '111 patent are not obvious; and (3) Actavis infringed: directly infringing the '111 claim 1 and inducing infringement of '626 claims 26, 31 and '195 claim 11.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Admissibility of Gadde fax | Fax shows Dr. Gadde communicated prior patient data to Orexigen in 2003; admissible as adoptive admission | Fax is hearsay and should be excluded; contents reflect prior uses and constitute prior art | Fax admissible limited to showing Gadde shared the data with Orexigen in 2003; not admissible to prove 1997/2000 treatments or as prior art |
| Written description for '195 claim 11 (dissolution ranges & method) | Spec (Tables 5,10 and a stated "standard dissolution test") conveys possession of claimed dissolution profile (USP Apparatus 2 or substantially equivalent) | Claimed ranges were assembled from disparate/speculative data measured by different methods (basket vs paddle); inadequate disclosure | Claim 11 satisfies written description by clear and convincing evidence; Table 10 and specification support the claimed profile |
| Obviousness of '111 and '626 claims (combine prior art Jain + O’Malley) | Claimed combination and sustained‑release fixed single‑dose composition are nonobvious; prior art did not teach combination for weight loss | A skilled artisan would be motivated to combine known bupropion weight‑loss data (Jain) with O’Malley teaching naltrexone combinations, with reasonable expectation of success | Claims are not obvious; prior art did not teach combination for weight loss and defendant’s argument relied on hindsight bias |
| Infringement (direct and inducement) | Actavis’s ANDA product meets claim limitations (sustained‑release, amounts, fixed single oral dosage) and labeling instructs administration that induces physicians/patients to practice claimed methods | Some tablets marginally fall outside dissolution ranges; divided‑infringement concerns for claims requiring diagnosis and administration | Plaintiff proved by preponderance that Actavis directly infringes '111 claim 1 and induces infringement of '626 claims 26,31 and '195 claim 11; divided‑infringement issues were moot for infringed claims |
Key Cases Cited
- Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (written‑description standard: specification must show possession of claimed invention)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (Graham framework and prohibition on hindsight in obviousness analysis)
- Graham v. John Deere Co., 383 U.S. 1 (1966) (sets factual inquiries for obviousness and role of secondary considerations)
- Global‑Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754 (2011) (induced infringement requires knowledge that induced acts constitute infringement)
- Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996) (claim construction is a question of law)
- Pfizer, Inc. v. Apotex, Inc., 480 F.3d 1348 (Fed. Cir. 2007) (requirement to show motivation to combine and reasonable expectation of success for obviousness)
- Bell Commc’ns Research, Inc. v. Vitalink Commc’ns Corp., 55 F.3d 615 (Fed. Cir. 1995) (an accused product that sometimes, but not always, practices a claimed method can still infringe)
- Prometheus Labs., Inc. v. Roxane Labs., Inc., 805 F.3d 1092 (Fed. Cir. 2015) (when challenger proves prima facie obviousness, patentee should present rebuttal evidence of secondary considerations)